Covetrus and MWI plan merger to build larger vet platform
Bottom line
Covetrus and MWI Animal Health have agreed to merge in a deal that would create a larger animal health platform spanning distribution, pharmacy, software, and practice services across companion, equine, and production animal markets. The transaction values MWI at $3.5 billion. Under the agreement announced February 18, 2026, MWI parent Cencora would receive $1.25 billion in cash, $800 million in perpetual preferred equity, and $1.45 billion in common equity, leaving Cencora with a 34.3% non-controlling stake in the combined company. The companies said the merger is intended to pair MWI’s supply chain and distribution reach with Covetrus’ technology and practice-management tools. The deal is still subject to customary closing conditions, including regulatory approvals, and Cencora has said it doesn’t expect the transaction to close before September 30, 2026. (investor.cencora.com)
Why it matters: For veterinary professionals, this is another sign that the supplier and practice-technology landscape is continuing to consolidate. If the deal closes, clinics could see a broader single-vendor offering that links product distribution with software, pharmacy, and operational services. That could simplify purchasing and workflow for some practices, but it also raises familiar questions about pricing leverage, vendor choice, integration, and how much influence one platform may have across the day-to-day business side of care. Covetrus itself has been private since its 2022 acquisition by Clayton, Dubilier & Rice and TPG, and the new structure would keep Cencora financially tied to the business even as it shifts focus toward its human-health core. Reuters also reported that one Wall Street analyst viewed the move as a logical way for Cencora to narrow its strategic focus. (covetrus.com)
What to watch: Watch for antitrust review, any customer-facing integration plans, and whether the companies spell out how ordering, software, pharmacy, and account relationships would change before a closing that currently isn’t expected before September 30, 2026. (stocktitan.net)
Covetrus and MWI Animal Health are planning a merger that would reshape a major slice of the veterinary supply chain. Announced February 18, 2026, the definitive agreement would combine MWI’s large-scale distribution business with Covetrus’ software, pharmacy, and practice-services operations to form what the companies describe as a more comprehensive animal health platform serving companion, equine, and production animal markets. The proposed transaction values MWI at $3.5 billion and would leave Cencora, MWI’s parent, with a 34.3% non-controlling stake in the combined company. (investor.cencora.com)
The deal also reflects a longer arc of consolidation in veterinary distribution and services. Covetrus itself was created through earlier combination activity and then was taken private in October 2022 by Clayton, Dubilier & Rice and TPG. MWI, meanwhile, has remained part of Cencora, formerly AmerisourceBergen, as that company increasingly emphasized its human-health distribution business. Reuters reported that Leerink Partners analyst Michael Cherny viewed MWI as having limited overlap with Cencora’s core human-health operations, making the transaction a strategic refocusing move for the parent company. (covetrus.com)
Financially, the structure is notable. According to Cencora’s announcement and related 8-K disclosure, Cencora would receive $1.25 billion in upfront cash, $800 million in perpetual payment-in-kind preferred units, and $1.45 billion in common units of CVET TopCo, the indirect parent of Covetrus. That mix gives Cencora continued exposure to the combined company’s performance while reducing its direct operating role in animal health. Cencora also said its reaffirmed fiscal 2026 guidance does not assume the transaction will close within its fiscal year ending September 30, 2026, a signal that regulatory review and integration planning could extend for months. (stocktitan.net)
Company leaders are framing the merger around efficiency and reach. Covetrus CEO Ben Wolin said the combination would let the company offer more solutions to more customers, improve logistics, create savings, and support stakeholders across the animal health ecosystem, including veterinarians and pet parents. Cencora CEO Bob Mauch said the transaction would position MWI with a partner focused specifically on animal health, while allowing Cencora to invest in other growth priorities. Trade coverage from Today’s Veterinary Business and AAHA echoed that pitch, emphasizing the prospect of a single organization spanning product distribution, supply chain support, pharmacy, software, and practice services. (investor.cencora.com)
Independent expert reaction appears limited so far, but the early outside read has been more strategic than celebratory. Reuters’ coverage highlighted the rationale for Cencora, while trade outlets have focused on how the combined company could broaden tools and access for practices. That said, the broader industry context suggests veterinary teams will likely judge this deal less by the announcement and more by execution: service levels, pricing, product availability, software interoperability, rebate structures, and whether clinics gain convenience without losing flexibility. That last point is an inference based on the nature of the businesses being combined and the sector’s existing consolidation pressures. (kelo.com)
Why it matters: For veterinary professionals, this merger sits at the intersection of two pressures clinics already feel every day: tighter operational margins and growing dependence on integrated vendors. A combined Covetrus-MWI could make life easier for some hospitals by tying together ordering, inventory, fulfillment, pharmacy, and business software under one umbrella. But it could also deepen concentration in a part of the market that already has outsized influence over what practices buy, how they buy it, and which digital tools they use to run the business side of care. For independent clinics especially, the appeal of a more seamless platform may come with tradeoffs around negotiating power and optionality. (investor.cencora.com)
There’s also a competitive angle. MWI is a major distributor, while Covetrus has positioned itself as a tech-enabled practice improvement company. Bringing those models together could create a stronger bundled offering for clinics at a time when veterinary purchasing, pharmacy fulfillment, and practice software are becoming more interconnected. If the companies can execute well, they may gain leverage by offering a more complete operating stack. If they can’t, practices may push harder for multi-vendor strategies that preserve flexibility. That assessment is an inference from the deal structure and the companies’ stated goals, rather than a direct claim from either company. (investor.cencora.com)
What to watch: The next milestones are regulatory review, any additional financing or governance disclosures, and practical details for customers. Veterinary professionals will want to watch for specifics on account management, ordering platforms, software roadmaps, distribution footprints, and whether the companies commit to a timeline for integration before the expected closing window, which currently extends beyond September 30, 2026. (stocktitan.net)